Supriya Lifescience Limited (NSE:SUPRIYA)

Market Cap	53.90B +7.2%
Revenue (ttm)	7.35B +9.7%
Net Income	1.85B +6.2%
EPS	23.04 +6.4%
Shares Out	80.48M
PE Ratio	29.06
Forward PE	22.95
Dividend	1.00 (0.15%)
Ex-Dividend Date	Sep 4, 2025

Volume	291,028
Average Volume	175,659
Open	669.65
Previous Close	669.65
Day's Range	669.65 - 694.90
52-Week Range	556.15 - 842.00
Beta	0.16
RSI	41.78
Earnings Date	Feb 9, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 515
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUPRIYA

Financial Performance

In fiscal year 2025, Supriya Lifescience's revenue was 6.96 billion, an increase of 22.12% compared to the previous year's 5.70 billion. Earnings were 1.88 billion, an increase of 57.80%.